Skip to main content
MIT Corporate Relations
MIT Corporate Relations
Search
×
Events
STEX25
Startups
opportunities
MIT ILP
Sign-In
Register Your Startup
Search
Search
×
STEX Home
Events
Corporates
Event Videos
Startups
STEX25
Featured
Videos
Startups
Search
News
opportunities
MIT ILP
User Menu and Search
Sign-In
Register Your Startup
Search
STEX Home
Toggle menu
Search
Sign-in
Register your startup
Events
Corporates
Event Videos
Startups
STEX25
Featured
Videos
Startups
Search
News
opportunities
MIT ILP
Back to search results
Asimov, Inc.
STEX25
Active dates:
May 1, 2018 - May 1, 2018
STEX25
STEX25 Participation:
May 1, 2018 - October 31, 2019
Company information
Contact
700 Main Street
Cambridge
,
Massachusetts
02139
United States
http://www.asimov.io
Empty Facebook link
https://www.linkedin.com/company/asimov-inc.
Empty YouTube link
Empty Twitter link
Elevator Pitch
Elevator Pitch
Living cells naturally perform remarkable feats of biochemical computation, but this capability is absent from biotechnology. Future applications in therapeutics, manufacturing, and agriculture will require the ability to program cells with new sense-and-response functions. We built a cell design platform called Cello that automatically compiles a DNA sequence from a high-level input/output specification. Using this platform, we are developing previously-impossible biotechnology applications.
Description
Description
Asimov's technology is a synthetic biology CAD platform (Cello) that we developed at MIT to program living cells with "genetic circuits". We have used it to design the most complex sense-and-response cell behaviors to date. We are now extending the platform to build genetic control modules for cell therapies and improved biologics manufacturing.